Dr. James Dixon is an Associate Professor at the School of Pharmacy, University of Nottingham, UK. He is the inventor of the gene delivery technology exploited by TherageniX for enhanced regenerative medicine. He is an expert in developing nanoparticle technologies for gene augmentation and provides the expertise to apply the his technology to vaccines, cancer therapy, regenerative medicine and gene correction/editing platform.
He also holds the IP to the technology at the University of Nottingham and was successful in managing the delivery system deliverables from the COVID-19 vaccine Innovate UK grant and clinical trial which is ongoing.
